STOCK TITAN

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
VYNE Therapeutics Inc. announced that its CEO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference. The company is developing therapies for immuno-inflammatory conditions.
Positive
  • None.
Negative
  • None.

BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts, on March 4, 2024. Management will also be available for 1-on-1 meetings with investors.

44th Annual TD Cowen Health Care Conference Presentation Details

Fireside Chat:Monday, March 4, 2024, at 10:30 a.m. ET
Speaker:David Domzalski, President and Chief Executive Officer
Registration:Webcast Link
1-on-1: Meetings:March 4, 2024
  

The replay of the webcast will be available on the VYNE website for 90 days following the conference.

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain inhibitors, which comprise its InhiBET™ platform, include a locally administered pan-BD BET inhibitor (VYN201) and an orally available BD2-selective BET inhibitor (VYN202) that were licensed from Tay Therapeutics Limited. 

For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
tyler.zeronda@vynetx.com


FAQ

When will David Domzalski participate in the fireside chat at TD Cowen 44th Annual Health Care Conference?

David Domzalski will participate in the fireside chat on March 4, 2024, at 10:30 a.m. ET.

Where will the fireside chat take place?

The fireside chat will take place at the Boston Marriott Copley Place in Boston, Massachusetts.

Will there be 1-on-1 meetings with investors?

Yes, management will be available for 1-on-1 meetings with investors on March 4, 2024.

Where can the webcast replay be accessed?

The webcast replay will be available on the VYNE website for 90 days following the conference.

VYNE Therapeutics Inc.

NASDAQ:VYNE

VYNE Rankings

VYNE Latest News

VYNE Stock Data

35.26M
13.38M
8.43%
51.92%
0.69%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRIDGEWATER